OTCMKTS:GNMSF Genmab A/S (GNMSF) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free GNMSF Stock Alerts $306.59 +5.59 (+1.86%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$296.36▼$306.5950-Day Range$262.26▼$313.0052-Week Range$262.00▼$432.30Volume1,205 shsAverage Volume573 shsMarket CapitalizationN/AP/E Ratio31.84Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Genmab A/S alerts: Email Address Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About Genmab A/S Stock (OTCMKTS:GNMSF)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GNMSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNMSF Stock News HeadlinesMarch 17, 2024 | finance.yahoo.com30 Biggest Biotechnology Companies in the WorldMarch 13, 2024 | finance.yahoo.comPassing of Genmab A/S’ Annual General MeetingMarch 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… February 21, 2024 | seekingalpha.comGenmab: Recent Updates Support The Growth NarrativeFebruary 20, 2024 | markets.businessinsider.com4 Analysts Assess Genmab: What You Need To KnowFebruary 15, 2024 | msn.comGenmab A/S’ New Regulation Risk – A Cause for Worry?February 15, 2024 | finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call TranscriptFebruary 15, 2024 | finance.yahoo.comNotice to Convene the Annual General Meeting of Genmab A/SMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 14, 2024 | finance.yahoo.comGenmab Files Annual Report with the U.S. Securities and Exchange CommissionFebruary 14, 2024 | finance.yahoo.comGenmab: Growth Is Still a Better ChoiceFebruary 2, 2024 | finance.yahoo.comTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical CancerJanuary 29, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For GenmabJanuary 25, 2024 | finance.yahoo.comGrant of Restricted Stock Units and Warrants to Employees in GenmabJanuary 22, 2024 | finance.yahoo.comGenmab Announces Decision in Arbitration Appeal under License Agreement with JanssenDecember 7, 2023 | finance.yahoo.comHRMY or GMAB: Which Is the Better Value Stock Right Now?November 8, 2023 | finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | msn.comGenmab reports 9M resultsNovember 7, 2023 | finance.yahoo.comGenmab Announces Financial Results for the First Nine Months of 2023November 2, 2023 | finance.yahoo.comGenmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)October 23, 2023 | msn.comGenmab and Seagen report positive data from Phase III TIVDAK trialOctober 23, 2023 | msn.comSeagen, Genmab update Phase 3 data for uterine cancer therapyOctober 17, 2023 | finance.yahoo.comGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023October 13, 2023 | benzinga.comWhat 13 Analyst Ratings Have To Say About GenmabSeptember 28, 2023 | finance.yahoo.comDiversified Stock Portfolio: 10 Sector ETFs and International ETFs to BuySeptember 25, 2023 | finance.yahoo.comEPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)September 25, 2023 | finance.yahoo.comEPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)See More Headlines Receive GNMSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:GNMSF CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728Fax45-7020-2729Employees2,204Year Founded1999Profitability EPS (Most Recent Fiscal Year)$9.63 Trailing P/E Ratio31.84 Forward P/E RatioN/A P/E GrowthN/ANet Income$631.91 million Net Margins26.50% Pretax Margin34.22% Return on Equity18.06% Return on Assets16.13% Debt Debt-to-Equity RatioN/A Current Ratio13.34 Quick Ratio13.32 Sales & Book Value Annual Sales$2.39 billion Price / SalesN/A Cash Flow$12.99 per share Price / Cash Flow23.61 Book Value$59.44 per share Price / Book5.16Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.01 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 63)Co-Founder, President & CEO Comp: $2.91MMr. Anthony Pagano (Age 46)Executive VP & CFO Comp: $1.03MMs. Birgitte Stephensen M.Sc. (Age 63)Executive VP & Chief Legal Officer Comp: $640.89kDr. Martine J. van Vugt Ph.D. (Age 53)Executive VP & Chief Strategy Officer Comp: $699.15kMr. Martin Schultz (Age 48)Senior Director of Clinical Operations & Non-Independent Director Comp: $116.53kDr. Tahamtan Ahmadi (Age 51)Executive VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.12MDr. Mijke Zachariasse Ph.D. (Age 50)Senior Director, Head of Antibody Research Materials & Non-Independent Director Comp: $160.22kMr. Takahiro Hamatani (Age 49)Senior Director of Finance Japan & Non-Independent Director Comp: $116.53kMr. Anthony Mancini (Age 53)Executive VP & COO Comp: $1.11MMr. Andrew CarlsenSenior Director, VP & Head of Investor RelationsMore ExecutivesKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAffymaxOTCMKTS:AFFYAlseres PharmaceuticalsOTCMKTS:ALSEView All Competitors GNMSF Stock Analysis - Frequently Asked Questions How have GNMSF shares performed in 2024? Genmab A/S's stock was trading at $315.6999 at the beginning of the year. Since then, GNMSF stock has decreased by 2.9% and is now trading at $306.59. View the best growth stocks for 2024 here. Are investors shorting Genmab A/S? Genmab A/S saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 170,800 shares, an increase of 24.1% from the February 14th total of 137,600 shares. Based on an average trading volume of 6,200 shares, the short-interest ratio is presently 27.5 days. View Genmab A/S's Short Interest. How were Genmab A/S's earnings last quarter? Genmab A/S (OTCMKTS:GNMSF) released its quarterly earnings results on Wednesday, February, 14th. The company reported $3.63 earnings per share for the quarter. The business earned $675.29 million during the quarter. Genmab A/S had a trailing twelve-month return on equity of 18.06% and a net margin of 26.50%. How do I buy shares of Genmab A/S? Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GNMSF) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.